Natera study shows Signatera MRD may help select breast cancer patients for non-surgical management

AstraZeneca reports positive phase III results for efzimfotase alfa in hypophosphatasia

Galapagos and Gilead expand collaboration to advance T cell engager programme

Sanofi secures EU approval for Rezurock in chronic graft-versus-host disease

Delonix Bioworks launches Phase 1 trial of next-generation MenB OMV vaccine DX-104

Hengrui Pharma and Braveheart Bio report positive Phase 2 results for HRS/BHB-1893 in oHCM

Innovent and Ollin Biosciences report IBI324 study data in wAMD and DME

Fusion Antibodies signs GBP250,000 IP transfer deal with Finn Therapeutics

GSK's bepirovirsen accepted for review in China as potential Hepatitis B functional cure

4DMedical secures EU approval for CT:VQ as EUR83m funding fuels European expansion

Aurinia Pharmaceuticals agrees to acquire Kezar Life Sciences

Lunit and CellCarta partner to advance AI-driven digital pathology in CDx development

Nektar Therapeutics presents rezpegaldesleukin data at 2026 AAD Annual Meeting

Amgen reports Repatha (evolocumab) cuts risk of first major CV events by 31% in high-risk patients without known significant atherosclerosis

Lilly presents Phase 3b Taltz (ixekizumab) plus Zepbound (tirzepatide) data at AAD Annual Meeting